On Monday, the U.S. Food and Drug Administration placed a partial clinical hold on Bright Minds Biosciences Inc.’s (NASDAQ:DRUG) investigational new drug application and related protocol for developmental and epileptic encephalopathies.
The regulatory pause impacts the company’s planned Phase 2 trial of BMB-101 in the United States, while other ongoing clinical studies proceed without interruption.
FDA Flags Juvenile Toxicity Concerns
The regulatory agency notified the biotechnology firm by email, citing observed toxicity in mice alongside inadequate pharmacokinetic and juvenile toxicity data to support proposed pediatric enrollment.
The planned randomized, double-blind, placebo-controlled study aims to evaluate the safety and efficacy of escalating BMB-101 doses up to a maximum tolerated dose for seizures linked to developmental and epileptic encephalopathies.
Bright Minds said researchers observed mouse toxicity only in that single species.
Drawing on internal toxicity reports, peer reviewers, and independent toxicology experts, the company believes the adverse mouse findings were incidental rather than drug-related.
Management emphasized that these viewpoints represent corporate interpretations rather than FDA findings.
Company Outlines Remediation Plans
Bright Minds expects the FDA’s formal Partial Clinical Hold Letter within 30 days, which will supply detailed recommendations regarding trial design and non-hold items.
The company intends to request immediate agency clarification, review the formal letter, and refine its protocol to address regulatory concerns. Management cautioned that future U.S. trials may require additional data or studies, offering no guarantee that the FDA will lift the hold.
Prior BMB-101 trials included approximately 90 participants across all company programs. In a Phase 1 study involving 64 healthy volunteers, subjects tolerated BMB-101 well across all doses and experienced zero serious adverse events.
Topline results from the Phase 2 Breakthrough trial were announced in January 2026. The data showed that 79.6% of adverse events were mild and 17.2% were moderate among 24 adult patients.
Six participants completed the primary treatment phase with a 63.3% median reduction in motor seizures. All five patients entering the open-label extension remain on therapy.
DRUG Price Action: Bright Minds shares traded 55% lower at $24.72 at last check on Monday, according to Benzinga Pro data.
Photo via Shutterstock
Recent Comments